Please assess the completion status of the following clinical trial:

Trial Title: Sinovac, Pandemic Influenza A/H1N1 Vaccine in 6 to 35 Months Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female aged between 6 and 35 months~2. Full-term birth, birth weight 2,500 grams or more~3. provided birth certification or vaccination card Parent(s) or legal guardian(s) are able to understand and sign the informed consent~Exclusion Criteria:~1. Cases, cured cases and close contact of influenza A (H1N1) virus~2. Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc~3. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain~4. Symptoms of acute infection within a week~5. Autoimmune disease or immunodeficiency~6. Congenital malformation, developmental disorders or serious chronic diseases (such as Down's syndrome, diabetes, sickle cell anemia or neurological disorders)~7. Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids~8. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws~9. History or family history of convulsions, epilepsy, brain disease and psychiatric~10. Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen~11. Guillain-Barre Syndrome~12. Administration of 2009-2010 seasonal vaccine~13. History of any blood products within 3 months~14. Administration of any other investigational research agents within 30 days~15. Administration of any live attenuated vaccine within 30 days~16. Administration of subunit or inactivated vaccines within 14 days~17. Be receiving anti-TB prophylaxis or therapy currently~18. Axillary temperature \> 37.0 centigrade at the time of dosing~19. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- Group 1: 7.5 μg pandemic influenza A/H1N1 vaccine (Type: EXPERIMENTAL): 120 subjects to receive two doses of 7.5 μg pandemic influenza A/H1N1 vaccine 21 days apart
- Group 2 : 15 μg pandemic influenza A/H1N1 vaccine (Type: EXPERIMENTAL): 120 subjects to receive two doses of 15 μg pandemic influenza A/H1N1 vaccine 21 days apart
- Group 3 : 7.5 μg seasonal trivalent vaccine (Type: SHAM_COMPARATOR): 60 subjects to receive two doses of 7.5 μg seasonal trivalent vaccine 21 days apart

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete